SSY Group falls 4% to 52-week low on US biotech investment curbs

SSY Group (1530.HK) fell 4.03% in Hong Kong trading to HK$13.35, touching a 52-week low.

The decline came after the US Treasury released a draft "Comprehensive Outbound Investment National Security Act" proposing restrictions on investment in China's biotech sector. Investors fear the policy could hamper equity financing and cross-border licensing partnerships for Chinese innovative drugmakers, dragging down the broader sector.

At the company level, SSY Group has been actively repurchasing shares, buying back 337,500 shares for HK$4.86 million on Oct. 14 and 800,000 shares for HK$11.65 million on Oct. 13. DBS initiated coverage in mid-October with a buy rating and a target price of HK$17.8, citing the company's pipeline and licensing growth potential. SSY Group previously secured a $1.25 billion upfront payment from Pfizer for a bispecific antibody licensing deal and reached an exclusive commercialization agreement with MindRank on MDR-001, an AI-designed oral GLP-1 weight-loss drug, with a potential total deal value of up to 1.75 billion yuan.

Source: HK Stock Market Update The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.